Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALA-002
- Development stage
- Unknown
- Lead developer
- PharmAla Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALA-002 is a novel, patented MDMA-class small molecule being developed by PharmAla Biotech. It is designed as a next-generation entactogen with an improved safety and toxicology profile compared to generic MDMA (3,4-methylenedioxymethamphetamine). The compound is primarily being investigated for the treatment of social anxiety in patients with Autism Spectrum Disorder (ASD), which is considered an orphan indication. PharmAla Biotech has partnered with the University of Sydney to advance ALA-002 into clinical development, following regulatory guidance from the UK's MHRA that allowed the program to proceed directly to clinical trials without further preclinical data. The company intends to move the candidate rapidly into Phase 2 clinical trials.
- Brand names
- LaNeo Gen 2
- Other names
- non-racemic 3,4-methylenedioxymethamphetaminenon-racemic MDMAnon-racemic midomafetamine
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on ALA-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALA-002.